KFDA approves Galvus, new oral treatment for type 2 diabetes
As a member of the new class of dipeptidyl peptidase IV inhibitors (DPP-IV), Galvus works through a novel mechanism of action by targeting the dysfunc...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
